Clinical Trials Logo

Meniere's Disease clinical trials

View clinical trials related to Meniere's Disease.

Filter by:

NCT ID: NCT01973114 Active, not recruiting - Menière's Disease Clinical Trials

Latanoprost for the Treatment of Menière's Disease

Start date: October 2013
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of Menière's disease.

NCT ID: NCT01729767 Recruiting - Meniere's Disease Clinical Trials

Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease

Start date: August 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Meniere's disease is a chronic illness that affects a substantial number of patients every year worldwide. The disease is characterized by intermittent episodes of vertigo lasting from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural pressure. It has recently been suggested that viral etiologies specially Herpes virus might be the underlying reason. The investigators study is a randomized, double- blinded placebo-controlled clinical trial in Amiralam Hospital. In this study the primary objective is to assess efficacy of Acyclovir in control of symptoms in patients with Meniere's disease specially their vertigo attacks. Inclusion criteria would be patient's willingness to participate in the study and follow ups, being 18 years old or older, having at least 2 vertigos per month each at least 20 min, interfering with function, and not on medication for Meniere's disease for at least 3 months before the trial. They should not have any history of allergy to Acyclovir, renal insufficiency or Creatinine above 1.5 mg/dl, hepatic enzymes more than three times normal, serious uncontrolled illness, be pregnant or nursing or have previous surgeries on Endolymphatic Sac. Participants will be randomly placed in 2 different arms getting either Acyclovir 400 mg or placebo (inert ingredient). They will take the medication for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, 6 month intervals.

NCT ID: NCT01526408 Terminated - Meniere's Disease Clinical Trials

Famvir for Treatment of Hearing in Unilateral Meniere's Disease

Famvir
Start date: December 2011
Phase: Phase 3
Study type: Interventional

The specific aim of this study is to determine the efficacy of treatment with famciclovir in unilateral Meniere's Disease patients, specifically whether hearing can be improved. The investigators will determine the percentage of unilateral Meniere's Disease patients experiencing an absence of hearing fluctuation after 3 months of treatment with famciclovir as compared to the placebo arm.

NCT ID: NCT01454726 Completed - Meniere's Disease Clinical Trials

Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease

TCDMD
Start date: January 2011
Phase: Phase 3
Study type: Interventional

The hypothesis of this study is that DiaoShi Jifa reduces the symptoms, such as dizziness in patients with Meniere's disease.

NCT ID: NCT01412177 Completed - Meniere's Disease Clinical Trials

OTO-104 for the Treatment of Meniere's Disease

Start date: November 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.

NCT ID: NCT01099046 Recruiting - Stress Clinical Trials

Stress Management Therapy for Meniere's Disease

SMT
Start date: January 2009
Phase: N/A
Study type: Interventional

Attacks in Meniere's disease, characterized by vertigo and hearing loss, are well known to occur repeatedly under stressed environment. Hitherto, its pathology was revealed to be inner ear hydrops through human temporal bone studies in 1938. For the pathogenesis of inner ear hydrops resulting in Meniere's attacks, plasma vasopressin elevation due to stress and V2 receptor overexpression in the inner ear could be essential as a basis of this disease. In the present study, we'd like to find the effective and feasible way to reduce plasma vasopressin level in patients with Meniere's disease.

NCT ID: NCT01084525 Completed - Meniere's Disease Clinical Trials

OTO-104 for Meniere's Disease

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of OTO-104 in subjects with unilateral Meniere's disease. The effectiveness of OTO-104 to reduce the symptoms of Meniere's disease will also be evaluated.

NCT ID: NCT00831688 Completed - Meniere's Disease Clinical Trials

Efficacy of Local Overpressure Treatment for Meniere's Disease

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study to date, is that no causal therapy for Meniere's disease has been discovered. Local overpressure treatment for Meniere's disease is a new treatment form that has been shown in animal and human experiments to reduce the endolymphatic hydrops, a condition that is generally believed to be the pathologic hallmark of Meniere's disease. This study analyzes the efficacy of local overpressure treatment by measuring subjective vertigo severity and objective audiovestibular function parameters.

NCT ID: NCT00802529 Completed - Meniere's Disease Clinical Trials

Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease.

NCT ID: NCT00500474 Completed - Meniere's Disease Clinical Trials

Effects of Endolymphatic Sac Drainage With Steroids for Meniere’s Disease

EDSS
Start date: April 1996
Phase: N/A
Study type: Interventional

Meniere's disease is a common inner ear disease with an incidence of 15-50 per 100,000 population. Since Meniere’s disease is thought to be triggered by an immune insult to inner ear, we examined intra-endolymphatic sac application of large doses of steroids as de novo treatment for intractable Meniere’s disease.